Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | PRNP | P04156 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL836066 | 0.92 | RXFP1 (0.48) | MEN1KMT2ALMNAPOLBRXFP1 | |
| SCHEMBL836059 | 0.86 | RHEB (0.50) | MEN1KMT2ALMNAPOLBRXFP1 | |
| SCHEMBL835287 | 0.86 | RXFP1 (0.43) | MEN1KMT2ALMNAPOLBRXFP1 | |
| SCHEMBL835284 | 0.86 | RXFP1 (0.43) | MEN1KMT2ALMNAPOLBRXFP1 | |
| SCHEMBL14302623 | 0.86 | LMNA (0.43) | MEN1KMT2ALMNAPOLBRXFP1 | |
| SCHEMBL835023 | 0.85 | KDM4E (0.42) | MEN1KMT2ARXFP1PRNPKDM4E | |
| SCHEMBL829644 | 0.85 | KDM4E (0.51) | MEN1KMT2ALMNARXFP1PRNP | |
| SCHEMBL14302622 | 0.84 | LMNA (0.41) | MEN1KMT2ALMNAPOLBRXFP1 | |
| SCHEMBL835024 | 0.83 | RXFP1 (0.43) | MEN1KMT2ARXFP1KDM4ENQO2 | |
| SCHEMBL829084 | 0.83 | MAPT (0.46) | MEN1KMT2ARXFP1KDM4EBRPF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143276-B2 | 4-thio substituted quinoline and naphthyridine compounds | XTL BIOPHARMACEUTICALS LTD. (IL) | 2012-03-27 | — | — | US | disclosed |
| US-8143276-B2 | 4-thio substituted quinoline and naphthyridine compounds | XTL BIOPHARMACEUTICALS LTD. (IL) | 2012-03-27 | — | — | US | disclosed |
| US-8143276-B2 | 4-thio substituted quinoline and naphthyridine compounds | XTL BIOPHARMACEUTICALS LTD. (IL) | 2012-03-27 | — | — | US | disclosed |
| EP-2061466-A2 | 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS | Xtl Biopharmaceuticals Ltd. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20090054477-A1 | 4-thio substituted quinoline and naphthyridine compounds | PRESIDIO PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090054477-A1 | 4-thio substituted quinoline and naphthyridine compounds | PRESIDIO PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090054477-A1 | 4-thio substituted quinoline and naphthyridine compounds | PRESIDIO PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | disclosed |
| WO-2008024423-A2 | 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS | XTL BIOPHARMACEUTICALS LTD. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024423-A2 | 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS | XTL BIOPHARMACEUTICALS LTD. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054477-A1 | 4-thio substituted quinoline and naphthyridine compounds | GTF3C4, HNF4A, TENT4A | MEN1 3979/4885KMT2A 1907/4885LMNA 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.